Onabotulinumtoxin A Versus Kenalog for Chronic Pelvic Pain
Summary
The goal of this study is to compare the effectiveness of two different medications used in intravaginal trigger point injections (injections into extremely painful areas of a muscle) to treat chronic pelvic pain. The study compares onabotulinumtoxinA (BOTOX®) (a drug prepared from the bacterial toxin botulin which temporarily paralyzes muscles) to Kenalog (a synthetic corticosteroid used as an anti-inflammatory agent).
Timeline
- Start
- 2015-08
- Primary completion
- 2018-03-26
- Completion
- 2018-09-24
Outcome
Missed primary endpoint
registry analysis (other test); Onabotulinumtoxin A vs Kenalog; p = 0.072; Kruskal-Wallis NCT02369068 ↗
registry analysis (other test); Onabotulinumtoxin A; p = 0.624; Kruskal-Wallis NCT02369068 ↗
registry analysis (other test); Onabotulinumtoxin A; p = 0.571; Kruskal-Wallis NCT02369068 ↗
registry analysis (other test); Onabotulinumtoxin A vs Kenalog; p = 0.285; Kruskal-Wallis NCT02369068 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Botulinum toxin type A | Protein / enzyme biologic | 200 iu | Other |
| Comparator | Triamcinolone Acetonide | Other / unclassified | 40 mg | Other |